Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (28199)	2/15/1999 9:13:00 AM
From: Henry Niman	Respond to of 32384

TD, Thanks for the heads up. I had seen that on Bloomberg: biocognizance.com

To: Arthur Radley who wrote (28199)	2/15/1999 7:07:00 PM
From: Cacaito	Read Replies (1) \| Respond to of 32384

Relativily, the BBIOY drug is not so bad, they reported same results gencitabine (standadard treatment group) when compared to Marimastat 25 mg group. Lower doses were worse. Side effects more on Marimastat group but not terrible. And this is in pancreatic cancer which are very aggresive and difficult to treat. Probably they will do better with other tumors. Marimastat is a metalloproteinase inhibitor that works as anti-angiogenesis, somewhat similar mechanisms as ENMD angiostatin/endostatin. They have long to go on this one.